NovoCure Ltd (NVCR) ニュース

ノボキュア、2024年度第3四半期の決算を発表

四半期純収益は前年比22%増の1億5500万ドル、2024年9月30日時点で治療中の患者数は過去最高の4113人に FDAは転移性非小細胞肺がんの治療薬としてOptune Lua...

Novocure nomme Christoph Brackmann au poste de directeur financier

Novocure (NASDAQ : NVCR) annonce aujourd’hui que Christoph Brackmann a été nommé au poste de directeur financier de la société (CFO). M...

Novocure ernennt Christoph Brackmann zum Finanzvorstand

Novocure (NASDAQ: NVCR) gab heute bekannt, dass Christoph Brackmann zum nächsten Finanzvorstand (CFO) des Unternehmens ernannt wurde. Christoph...

Form 8-K - Current report

Novocure Appoints Christoph Brackmann as Chief Financial Officer

Novocure (NASDAQ: NVCR) announced today that Christoph Brackmann has been appointed as the company’s next Chief Financial Officer (CFO). Mr...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Novocure Reports Third Quarter 2024 Financial Results

Quarterly net revenues of $155 million, up 22% year-over-year, with record 4,113 active patients on therapy as of September 30, 2024 FDA...

FDA genehmigt Optune Lua® von Novocure zur Behandlung des metastasierenden nicht-kleinzelligen Lungenkarzinoms

Als erste Behandlung ihrer Art für das metastasierende NSCLC ist Optune Lua in Kombination mit PD-1/PD-L1-Inhibitoren oder Docetaxel bei...

ノボキュアのOptune Lua®、転移性非小細胞肺がんの治療用としてFDAの承認を取得

転移性非小細胞肺がんに対するこの種の治療として初のOptune Luaは、プラチナ製剤ベースのレジメンによる治療中または治療後に疾患進行が認められた転移性非...

FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in...

Form 8-K - Current report

Form 3 - Initial statement of beneficial ownership of securities

Novocure to Report Third Quarter 2024 Financial Results

Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial...

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy

Novocure (NASDAQ: NVCR) announced today it will present a real-world analysis of usage of its Tumor Treating Fields (TTFields) therapy and...